Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis

Hepatology

Volumn 45, Issue 6, 2007, Pages 1366-1374

  Yamaguchi, Kanji ^a   Yang, Liu ^a   McCall, Shannon ^a   Huang, Jiawen ^a   Xing, Xian Yu ^b   Pandey, Sanjay K ^b   Bhanot, Sanjay ^b   Monia, Brett P ^b   Li, Yin Xiong ^a   Diehl, Anna Mae ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIACYLGLYCEROL ACYLTRANSFERASE; DIACYLGLYCEROL ACYLTRANSFERASE 2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; FATTY LIVER; GENE EXPRESSION; GENE SEQUENCE; INSULIN SENSITIVITY; LIPID PEROXIDATION; LIVER FIBROSIS; LIVER INJURY; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL; RISK FACTOR;

ADIPONECTIN; ANIMAL FEED; ANIMALS; BLOOD GLUCOSE; CHOLINE; CYTOCHROME P-450 CYP2E1; DIACYLGLYCEROL O-ACYLTRANSFERASE; DISEASE MODELS, ANIMAL; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; HEPATOCYTES; INSULIN; LIPID PEROXIDATION; LIVER CIRRHOSIS; MALE; METHIONINE; MICE; MICE, MUTANT STRAINS; OBESITY; OLIGORIBONUCLEOTIDES, ANTISENSE; OXIDATIVE STRESS; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34250356015     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21655     Document Type: Article

References (32)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
2. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. HEPATOLOGY 2004;40:1387-1395
3. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 2003;289:3000-3004.
4. Diehl AM Clarke J, Brancati F. Insulin resistance syndrome and nonalcoholic fatty liver disease. Endocr Pract 2003;9(Suppl 2):93-96.
5. Cases S, Stone SJ, Zhou P, Yen E, Tow B, Lardizabal KD, et al. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J Biol Chem 2001;276:38870-38876.
6. Yamazaki T, Sasaki E, Kaldnuma C, Yano T, Miura S, Ezaki O. Increased very low density lipoprotein secretion and gonadal fat mass in mice overexpressing liver DGAT1. J Biol Chem 2005;280:21506-21514.
7. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. HEPATOLOGY 2002;35:367-372.
8. Day CP, James OF. Steatohepatitis: a tale of two "hit"? Gastroenterology 1998;114:842-845.
9. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease. Mayo Clinic Proc 1980;55:434-438.
10. Yu XX, Murray SF, Pandey SK, Booten SL, Bao D, Song XZ, et al. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. HEPATOLOGY 2005;42: 362-371.
11. Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, et al. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 2004;287:G1035-G1043.
12. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, et al. Evidence that diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996;84:491-495.
13. Choi SS, Sicklick JK, Ma Q, Yang L, Huang J, Qi Y, et al. Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in mice. HEPATOLOGY 2006;44:1267-1277.
14. Sicklick JK, Li Y-X, Choi SS, Qi Y, Chen W, Bustamante M, Huang J, et al. Role for Hedgehog signaling in hepatic stellate cell activation and viability. Lab Invest 2005;85:1368-1380.
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-408.
16. Yata Y, Gotwals P, Koteliansky V, Rockey DC. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. HEPATOLOGY 2002;35:1022-1030.
17. Lopez-De Leon A, Rojkind M. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem 1985;33:737-743.
18. Brunt EM, Janney CG, Di, Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
19. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 2006;87:1-16.
20. Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003;125:1796-1807.
21. Adams MA, Talwalkar JA. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol 2006;40(3 Suppl 1):S34-S38.
22. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-750.
23. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 2003;52:1-8.
24. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000;105:1067-1075.
25. Pacifici EH, McLeod LL, Peterson H, Sevanian A. Linoleic acid hydroperoxide-induced peroxidation of endothelial cell phospholipids and cytotoxicity. Free Radic Biol Med 1994;17:285-295.
26. Penumetcha M, Khan N, Parthasarathy S. Dietary oxidized fatty acids; an atherogenic risk? J Lipid Res 2000;41:1473-1480.
27. Pegorier JP, Le May C, Girard J. Control of gene expression by fatty acids. J Nutr 2004;134:2444S-2449S.
28. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001;281:G1135-G1139.
29. Schulet AM, Wood PA. Mouse models for disorders of mitochondrial fatty acid beta-oxidation. ILAR J 2002;43(2):57-65.
30. Duivenvoorden I, Teusink B, Rensen PC, Kuipers F, Romijn JA, Havekes LM, et al. Acute inhibition of hepatic beta-oxidation in APOE*3Leiden mice does not affect hepatic VLDL secretion or insulin sensitivity. J Lipid Res 2005;46:988-993.
31. Tang Y, Osawa H, Onuma H, Nishimiya T, Ochi M, Sugita A, et al. Phosphodiesterase 3B gene expression is enhanced in the liver but reduced in the adipose tissue of obese insulin resistant db/db mouse. Diabetes Res Clin Pract 2001;54:145-155.
32. Tartaglia LA. The leptin teceptot. J Biol Chem 1997;272:6093-60966.